Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest refractory angina Stories

2014-01-06 16:27:53

Requires Premarket Approval for ECP Devices for Other Intended Uses WESTBURY, N.Y., Jan. 6, 2014 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices including EECP(®) (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that the U.S. Food and Drug Administration (FDA), Department of Health and Human Services,...

2013-11-06 08:29:08

-Primary Efficacy Endpoint Achieved in Multicenter, Prospective, Randomized, Sham-Controlled Trial Assessing Novel Percutaneous Device in Untreatable Patients Severely Disabled by Angina- TSX Venture Exchange: NVC VANCOUVER, Nov. 6, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc Reducer(TM), a novel percutaneous device for the treatment of refractory angina. The data shows that...

2013-08-15 08:28:17

--Year-over-Year Revenues Increased 71% from Robust Growth in Contract Manufacturing and Consulting Services Revenues-- TSX Venture Exchange: NVC VANCOUVER, Aug. 15, 2013 /PRNewswire/ - Neovasc Inc. ("Neovasc") (TSXV: NVC), today announced financial results for the three and six months ended June 30, 2013. "We continued to deliver on our planned progress in all of Neovasc's programs during the second quarter," commented Alexei Marko, chief executive officer of Neovasc. ...

2013-05-28 08:28:22

--Increased Year-over-Year Revenues by 17%, Driven by Growth in Contract Manufacturing and Consulting Services to Transcatheter Heart ValveCustomers----Completed Patient Enrollment in Neovasc Reducer(TM) COSIRA Trial----Presented Positive Reducer and Tiara(TM) Mitral Valve Program Data at 2013 EuroPCR-- TSX Venture Exchange: NVC VANCOUVER, May 28, 2013 /CNW/ - Neovasc Inc. ("Neovasc") (TSXV: NVC), today announced financial results for the three months ended March 31, 2013. "We...

2013-05-21 08:28:33

-Initial Data from Patient Registries Shows the Reducer Significantly Improves Angina Scores at Six Months Post-Implantation- TSX Venture Exchange: NVC PARIS and VANCOUVER, May 21, 2013 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today reported initial data from open label patient Registries that are tracking the progress of refractory angina patients implanted with the Neovasc Reducer(TM), a novel percutaneous device that...

2013-05-13 08:28:25

-Full Data from COSIRA Trial Expected Around Year's End--Initial Data from Reducer Patient Registries To Be Presented at EuroPCR 2013- TSX Venture Exchange: NVC VANCOUVER, May 13, 2013 /CNW/ - Neovasc Inc. (TSXV: NVC), today announced the completion of patient enrollment in its COSIRA trial designed to further assess the efficacy and safety of the Neovasc Reducer(TM), a novel percutaneous device for the treatment of refractory angina.  The COSIRA (Coronary Sinus Reducer for...

2013-04-29 08:27:06

--Grew Annual Revenues 49% Year-Over-Year to $7.8 Million----Significantly Advanced New Product Pipeline Programs-- TSX Venture Exchange: NVC VANCOUVER, April 29, 2013 /CNW/ - Neovasc Inc. ("Neovasc") (TSXV: NVC), today announced financial results for the year ended December 31, 2012. "In 2012 we made substantial progress in every area of our business," said Alexei Marko, CEO of Neovasc.  "We continued our robust revenue growth, achieving good sales gains in all three of our...

2013-02-28 08:29:28

-Trial Further Assessing Efficacy of Neovasc Reducer(TM) in Treatment of Refractory Angina Expected to Complete Patient Enrollment in Coming Months-   -Company Also Announces Issuance of Incentive Options to Directors, Management and Staff- TSX Venture Exchange: NVC VANCOUVER, Feb. 28, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that the clinical protocol for its COSIRA (coronary sinus reducer for treatment of refractory angina) trial has been published in...

2012-11-26 08:24:23

--41% Year-Over-Year Revenue Increase for the Quarter--  --Neovasc Reducer(TM) and Tiara(TM) Transcatheter Mitral Valve Data Presented at TCT 2012--  TSX Venture Exchange: NVC VANCOUVER, Nov. 26, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced financial results for the three months ended September 30, 2012. "In the third quarter, we continued to report robust increases in sales, with revenues for the quarter topping two million dollars," commented Alexei...

2012-10-23 07:28:52

--Researchers Presented Positive Preclinical Data That Set the Stage for Longer-Term Tiara Studies Now Underway and Human Trials Planned for 2013-- --Researchers Also Presented Preliminary Registry Study Results Showing Improved Clinical  Status in Refractory Angina Patients Implanted with Neovasc Reducer(TM)-- TSX Venture Exchange: NVC VANCOUVER, Oct. 23, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that its Tiara(TM) transcatheter mitral valve in...